Why Is ACADIA PHARMACEUTICA (ACAD) Stock Down Today?

ACADIA Pharmaceuticals shares fell 4.12% to $29.31 in morning trading on August 26 despite multiple analysts raising price targets in the prior 36 hours. The stock opened with a $30.90 gap up but quickly reversed lower, hitting a session low of $29.31 by 10:15 AM ET. The decline came as the stock traded near the top of its 52-week range and as recent insider sales continued.

What Happened

Deutsche Bank, Morgan Stanley, and Citigroup all raised price targets for ACADIA in the past 36 hours, with Deutsche Bank setting a $38 target, Morgan Stanley at $28, and Citigroup at $40. H.C. Wainwright also reiterated its rating on the stock following European Union approval of Acadia’s DAYBU for Rett syndrome patients aged five and older. Despite these developments, the stock opened with a 1.1% gap up and quickly reversed course. The European regulatory approval was announced earlier in the week, and the stock had already risen 8.1% over the previous eight sessions. Meanwhile, the company’s CFO and other executives sold shares in recent weeks, with four insider sales totaling $1.4 million reported in the last 90 days.

What The Data Shows

The stock traded at a 52-week high of $30.96 just before the session began but fell to a 52-week low of $19.69 during the same period. The current price of $29.31 is near the 52-week high. The session volume of 0.2 million shares is below the 3-month daily average. The stock has printed one fresh 52-week high and six fresh 52-week lows on August 26. The company’s fundamentals include a market cap of $5.1 billion, a P/E ratio of 13.9, and a net margin of 33.4%. Revenue grew 11.8% in the trailing twelve months.

What To Watch

The stock is currently trading near key technical levels and faces coverage breadth to monitor as analysts continue to adjust their outlooks. No earnings report is scheduled in the near term.